Clinical trials
Cytopenia trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
46 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 24 |
| Recruiting | 12 |
| Terminated | 3 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
| Not yet recruiting | 1 |
| Enrolling by invitation | 1 |
| No longer available | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ortho Pharmaceuticals | 6 |
| Sandoz | 6 |
| National Heart, Lung, and Blood Institute (NHLBI) | 3 |
| Takeda | 3 |
| Amgen | 2 |
| Children's Hospital Medical Center, Cincinnati | 2 |
| National Cancer Institute (NCI) | 2 |
| Traws Pharma, Inc. | 2 |
| Baylor College of Medicine | 1 |
| Bellicum Pharmaceuticals | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cytopenia | 46 |
| HIV Infections | 16 |
| Acquired Immunodeficiency Syndrome | 14 |
| Myelodysplastic Syndromes | 14 |
| Anemia | 10 |
| Leukemia, Myeloid, Acute | 7 |
| Neutropenia | 7 |
| AIDS-Related Complex | 5 |
| Hematologic Diseases | 5 |
| Anemia, Aplastic | 4 |
Trials
Showing 1 to 25 of 46. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.